4.06  -0.26 (-6.02%)		08-18 16:00
Open: 4.31 High: 4.35 Volume: 869,276		Pre. Close: 4.32 Low: 4.05 Market Cap: 422(M)

Short term
Mid term
Targets	6-month :	5.21	1-year :	6.09
Resists	First :	4.46	Second :	5.21
Pivot price	4.1
Supports	First :	3.89	Second :	3.53
MAs	MA(5) :	4.27	MA(20) :	4.06
	MA(100) :	3.97	MA(250) :	3.95
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	74.7	D(3) :	81.6
RSI	RSI(14): 51.3
52-week	High :	6.42	Low :	2.71

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LRMR ] has closed above bottom band by 45.1%. Bollinger Bands are 5.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.36 - 4.38	4.38 - 4.4
Low:	3.99 - 4.02	4.02 - 4.04
Close:	4.02 - 4.06	4.06 - 4.1

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.

Tue, 18 Aug 2026
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits

Thu, 13 Aug 2026
Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat

Thu, 13 Aug 2026
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat

Tue, 04 Aug 2026
Larimar Therapeutics Reports Positive Longer-Term Nomlabofusp Data and Progress Toward Rolling BLA Submission for Friedreich’s Ataxia - Quiver Quantitative

Thu, 23 Jul 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire

Wed, 15 Jul 2026
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	104 (M)
Shares Float	60 (M)
Held by Insiders	1.1 (%)
Held by Institutions	86.6 (%)
Shares Short	11,300 (K)
Shares Short P.Month	10,540 (K)

EPS	-2.01
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.5
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-71 %
Return on Equity (ttm)	-139.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.73
Qtrly Earnings Growth	0 %
Operating Cash Flow	-156 (M)
Levered Free Cash Flow	-94 (M)

PE Ratio	-2.02
PEG Ratio	0
Price to Book value	2.68
Price to Sales	0
Price to Cash Flow	-2.71

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.